Table 1 Cases who achieved complete response for more than 2 years in the literature
Case 1 | Case 2 | Case 3 | Case 4 | Present case | |
|---|---|---|---|---|---|
Reported year [reference] | 2011 [8] | 2011 [8] | 2013 [9] | 2013 [10] | 2014 |
Age/sex | 70/male | 69/male | 71/male | 74/male | 83/male |
Background liver disease | Hepatitis C | Hepatitis C | Hepatitis C | Hepatitis B | Non-viral, non-alcoholic |
Tumor status at sorafenib initiation | |||||
Number | Single | Not described | Multiple | Single | - |
Location | Not described | Three hepatic lesions | Segment IV and VII | Posterior segment | Right lobe |
Maximum size | 6 × 5 cm | Not described | 9 cm | 8.6 × 5.7 cm | - |
Extension | Vascular invasion | Portal vein thrombosis | Portal vein thrombosis | Vertebral metastasis | Lung metastasis |
Pathological diagnosis | None (based on the computed tomography image) | None (based on the computed tomography image) | Poorly/moderately differentiated hepatocellular carcinoma | Moderately differentiated hepatocellular carcinoma | Poorly differentiated hepatocellular carcinoma |
Pretreatment before sorafenib | None | Not described | Synchro-level, Vitamin E | TACE → PEIT, RFA | TACE + RFA → HAIC (5-FU + CDDP) |
Doses of sorafenib (period) | |||||
Initial dose | Not described | 800 mg/day (10 days) | 800 mg/day (2 months) | 800 mg/day (2 weeks) | 400 mg/day (1 month) |
Second dose | → 400 mg/day (55 months) | → 400 mg/day (3 months) | → 400 mg/day (18 months) | → 400 mg/day (60 months) | → 200 mg/day (1 months) |
Third dose | → 400 mg/2 days (57 months) | → 800 mg/day (4 months) | |||
Fourth dose | → 400 mg/day (2 months) | ||||
Last doses | → 200 → 100 → 200 mg/day (34 months) | ||||
Total period of sorafenib | 60 months | 62 months | 20 months | 60 months | 42 months |
Period of complete response | <27 months | 38 months | 28 months | 54 months | 34 months |
Reported status | Alive | Alive | Alive | Alive | Alive |